These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25256963)

  • 1. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
    Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
    Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
    Alchalby H; Kröger N
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing patients with myelofibrosis and low platelet counts.
    Al-Ali HK; Vannucchi AM
    Ann Hematol; 2017 Apr; 96(4):537-548. PubMed ID: 27209535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
    Shanavas M; Gupta V
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Myelofibrosis: A Moving Target.
    Cerquozzi S; Farhadfar N; Tefferi A
    Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myelofibrosis: to transplant or not to transplant?
    Devlin R; Gupta V
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):543-551. PubMed ID: 27913527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
    Viswabandya A; Devlin R; Gupta V
    Curr Hematol Malig Rep; 2016 Feb; 11(1):6-11. PubMed ID: 26659587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical management of myelofibrosis with ruxolitinib.
    Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
    Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.
    Gupta V; Hari P; Hoffman R
    Blood; 2012 Aug; 120(7):1367-79. PubMed ID: 22700718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
    Shanavas M; Popat U; Michaelis LC; Fauble V; McLornan D; Klisovic R; Mascarenhas J; Tamari R; Arcasoy MO; Davies J; Gergis U; Ukaegbu OC; Kamble RT; Storring JM; Majhail NS; Romee R; Verstovsek S; Pagliuca A; Vasu S; Ernst B; Atenafu EG; Hanif A; Champlin R; Hari P; Gupta V
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):432-40. PubMed ID: 26493563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
    Gupta V; Gotlib J; Radich JP; Kröger NM; Rondelli D; Verstovsek S; Deeg HJ
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1274-81. PubMed ID: 24680977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem-cell transplantation for myelofibrosis.
    Lavi N; Rowe JM; Zuckerman T
    Curr Opin Hematol; 2017 Nov; 24(6):475-480. PubMed ID: 28832353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.
    Jaekel N; Behre G; Behning A; Wickenhauser C; Lange T; Niederwieser D; Al-Ali HK
    Bone Marrow Transplant; 2014 Feb; 49(2):179-84. PubMed ID: 24292520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
    El Fakih R; Popat U
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How I treat myelofibrosis.
    Cervantes F
    Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of JAK inhibition in myelofibrosis and beyond.
    Mascarenhas JO; Cross NC; Mesa RA
    Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.
    Polverelli N; Farina M; D'Adda M; Damiani E; Grazioli L; Leoni A; Malagola M; Bernardi S; Russo D
    Cells; 2022 Feb; 11(3):. PubMed ID: 35159362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
    Saeed I; McLornan D; Harrison CN
    Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic stem cell transplantation for myelofibrosis in 2012.
    McLornan DP; Mead AJ; Jackson G; Harrison CN
    Br J Haematol; 2012 May; 157(4):413-25. PubMed ID: 22463701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.